Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | FADS1 | O60427 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30965223 | 1.00 | TSHR (0.54) | TSHRLMNAMAP2K4MAPK1MAPK6 | |
| SCHEMBL14979221 | 0.88 | MAP2K4 (0.54) | TSHRLMNAMAP2K4MAPK1MAPK6 | |
| SCHEMBL7581326 | 0.81 | LMNA (0.49) | LMNAKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL11756961 | 0.81 | PDPK1 (0.51) | LMNAKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL3363383 | 0.81 | LMNA (0.49) | LMNAMAP2K4KDM4EMAPTMEN1 | |
| SCHEMBL14487354 | 0.81 | MAP2K4 (0.56) | LMNAMAP2K4MAPK1MAPK6KDM4E | |
| SCHEMBL14979247 | 0.80 | SMN1; SMN2 (0.55) | LMNAKDM4EMAPTALDH1A1NTRK1 | |
| SCHEMBL5953391 | 0.80 | MAP2K4 (0.43) | TSHRMAP2K4MAPK1MAPK6ITK | |
| SCHEMBL10931244 | 0.80 | LMNA (0.48) | LMNAMAP2K4KDM4EMAPTMEN1 | |
| SCHEMBL10927575 | 0.80 | LMNA (0.48) | LMNAMAP2K4KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024085695-A1 | NOVEL ALTIRATINIB DERIVATIVE, MANUFACTURING METHOD THEREFOR, AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF SKIN PIGMENTATION | 재단법인 아산사회복지재단 | 2024-04-25 | — | — | WO | disclosed |
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2781508-B1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-9725442-B2 | Heterocyclic derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9688662-B2 | N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688662-B2 | N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| EP-2989091-B1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2752410-B1 | HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| WO-2014161808-A1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]JPYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-09 | — | — | WO | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| EP-2781508-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP Biosciences Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| EP-2781508-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP Biosciences Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-09-18 | — | — | US | disclosed |
| EP-2752410-A1 | HETEROCYCLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi & Co., Ltd. (JP) | 2014-07-09 | — | — | EP | disclosed |
| CN-103391936-A | Anticancer agent | NAT UNIV CORP UNIV TOKYO | 2013-11-13 | — | — | CN | disclosed |
| WO-2013071880-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | 山东亨利医药科技有限责任公司 (CN) | 2013-05-23 | — | — | WO | disclosed |
| CN-1922175-A | As 5-HT4Indazole-carboxamide compounds as receptor agonists | THERAVANCE INC (US) | 2007-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275074-A1 | HETEROCYCLIC DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | PTGDR, PTGDR2, PTGER4 | TSHR 499/4885LMNA 3019/4885MAP2K4 2710/4885 |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, NR3C2 | TSHR 663/4885LMNA 1370/4885MAP2K4 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.